| The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). | |
| | |
MedLine Citation:
|
PMID: 23194488 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: Galectin-3 is a new biomarker involved in inflammation and fibrogenesis and could therefore contribute to myocardial remodeling. We examined the prognostic value of baseline galectin-3 in a substudy involving approximately 30% of participants in the CORONA study. METHODS: Patients (n = 1462) aged >60 years with systolic, ischemic heart failure (HF) were randomized to 10 mg/d rosuvastatin or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, or stroke (n = 408). RESULTS: In the unadjusted analysis, galectin-3 was associated with all end points considered, except hospitalization for worsening of HF. In multivariable analyses, adjusting for other clinical and biochemical predictor variables, galectin-3 was significantly associated with the primary end point (hazard ratio [HR] 1.53 [1.10-2.12], P = .011) as well as all-cause (HR 1.61 [1.20-2.29], P = .002) and cardiovascular mortality (HR 1.70 [1.19-2.42], P = .003), sudden death (HR 1.83 [1.14-2.94], P = .012), and the coronary end point (HR 1.48 [1.03-2.12], P = .035). However, when N-terminal pro-brain natriuretic peptide was added to the model, galectin-3 association with the end points was markedly attenuated and no longer significant. CONCLUSIONS: Galectin-3 is not associated with outcome in older patients with advanced chronic systolic HF of ischemic etiology when adjusting for N-terminal pro-brain natriuretic peptide and may therefore have limited use in the prognostication of elderly patients with systolic HF in clinical practice. |
| | |
Authors:
|
Lars Gullestad; Thor Ueland; John Kjekshus; Ståle H Nymo; Johannes Hulthe; Pieter Muntendam; John J V McMurray; John Wikstrand; Pål Aukrust |
Related Documents
:
|
21521728 - Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and tria... 21450598 - Health and cost consequences of early versus late invasive strategy after thrombolysis ... 21135978 - Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluti... 21414598 - Effect of emergency department in-hospital tele-electrocardiographic triage and interve... 11988638 - Role of nitric oxide in the regulation of substrate metabolism in heart failure. 7428148 - Concentrations of magnesium, calcium, potassium, and sodium in human heart muscle after... |
Publication Detail:
|
Type: Journal Article Date: 2012-10-29 |
Journal Detail:
|
Title: American heart journal Volume: 164 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-11-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 878-83 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 Mosby, Inc. All rights reserved. |
Affiliation:
|
Deparment of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: lars.gullestad@medisin.uio.no. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart f...
Next Document: Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in pat...